SanBio Company Limited (SNBIF) Fair Value & Analysis
Healthcare · US · Market cap $1.3B
What is SanBio Company Limited really worth?
SanBio Company Limited
SNBIF · US
Below-average quality, trading 61% below our fair value of $42.61.
Risks
Fair value as of: Aug 28, 2026
From 1 valuation models · updated 7 days ago
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($28.12). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($28.12 to $53.26) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $0.0001 – $16.75 · fair‑value band $28.12 – $53.26 · the $16.45 price screens below the $42.61 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.
Analysis
SanBio Company Limited (SNBIF) currently trades at $16.45, while our model-based Fair Value estimate is $42.61, implying the stock looks roughly 61.4% undervalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Revenue declined 86.7% year over year. It earns a return on equity of −43.2%. Fundamentals as of Aug 28, 2026
Our scenario range runs from $28.12 (bear case) to $53.26 (bull case); at $16.45, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 327% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at 159%, SNBIF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when SNBIF reaches fair value
Put SNBIF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 70
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan.
Full company description
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SanBio Company Limited reported revenue of ¥0 in FY2025 versus ¥22.9M in FY2021. Reported net income was −¥2.9B in FY2025.
Watch SNBIF: get an alert when its fair value changes →
Peer Group
Biotechnology · 636 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| CSL Limited CSL | A$173.88 | A$142.22 | −18% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE 22UA | €80.60 | €52.92 | −34% |
Compare SanBio Company Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is SanBio Company Limited (SNBIF) overvalued or undervalued?
What is the fair value of SNBIF?
What is the quality score of SNBIF?
What is the net profit margin of SNBIF?
Watch SanBio Company Limited in the live analysis
One click puts SanBio Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.